Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma) for Aumolertinib, a third‑generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR‑TKI) used in the treatment of non‑small cell lung cancer (NSCLC).
Under the terms of the agreement, Hansoh Pharma has granted Glenmark exclusive rights to develop and commercialise Aumolertinib across specified regions, including the Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS and selected Caribbean countries. Hansoh Pharma will receive an upfront payment in low double‑digit millions of U.S. dollars, followed by potential regulatory and commercial milestone payments that could total over US $1 billion, in addition to tiered royalties on net sales in the licensed territories.
Aumolertinib, marketed under trade names such as Ameile® in China and Aumseqa® in the United Kingdom and Europe, has received marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and approvals from the National Medical Products Administration (NMPA) in China for multiple indications in locally advanced or metastatic EGFR‑mutated NSCLC. The drug’s approvals include first‑line and second‑line treatments for patients with activating EGFR mutations, and additional indications in China covering post‑chemoradiotherapy and adjuvant settings.
The licensing agreement strengthens Glenmark’s oncology strategy across high‑potential markets, broadening its commercial pipeline and expanding access to advanced treatment options for patients with EGFR‑mutated lung cancer.
The collaboration reinforces Glenmark’s focus on enhancing its innovative oncology portfolio and serving patients in regions covered by the agreement.
